Mineralys Therapeutics, Inc. (MLYS)
After hours:
| Previous close | 14.65 |
| Open | 14.68 |
| Bid | 14.20 x 100 |
| Ask | 14.31 x 100 |
| Day's range | 13.76 - 15.00 |
| 52-week range | 5.85 - 17.44 |
| Volume | |
| Avg. volume | 157,616 |
| Market cap | 728.628M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.83 |
GlobeNewswireMineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 – – Ongoing Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is anticipated to deliver topline data in Q4 2024 to Q1 2025 – – Conference call today at 8:30 a.m. ET – RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a
- GlobeNewswire
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024. Bank of America Securities Health Care Conference:D
- GlobeNewswire
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024. Thursday, May 9th @ 8:30 a.m. ETDomestic:1-888-886-7786International
